SIMULTANEOUS DETERMINATION OF BLOOD GROUPS AND SERUM ANTIBODIES BY FLOW CYTOMETRY

This technology comprises novel flow cytometric methods for the simultaneous detection of ABO and Rh(D) antigens in human red blood cells, isoantibodies to erythrocyte antigens A and B in serum/plasma, and clinically important alloimmune antibodies to blood group antigens in serum/plasma. The methods include a unique combination of fluorescently labeled antibodies to A, B, and Rh(d) antigens, different sized beads coated with blood group substances A and B, and the differential fluorescent labeling of reagent red blood cells for flow cytometric analysis.

In contrast to current clinical methods, the present invention does not require hemagglutination reactions. Rather, flow cytometry offers the distinct advantage of concurrent multiple antigen and antibody analysis in a single undivided sample. The routine ABO and Rh(D) typing and antibody screening of human blood can be determined in three individual reactions, compared to the seven to ten tests required using current blood bank technology. Recurring reagent costs can be reduced compared to conventional agglutination tests because fewer reactions are required with the flow cytometric system. This system offers excellent precision, sensitivity, speed, and objective determination of blood group typing and serum antibody screening. Moreover, the integrated flow cytometric methodology is amenable to automation and computerized data evaluation.

If you would like to receive further information about this technology and potential licensing opportunities, please contact:

Joel B. Kirschbaum, Ph.D.
Director & Senior Technology Portfolio Manager
(415) 353-4462 phone
(415) 348-1579 fax
Joel Kirschbaum, Ph.D.

Reference: OTM Case #SF97-092